Loading…

Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes

We previously reported the development of PE38KDEL-loaded anti-HER2 poly(lactic-co-glycolic acid) (PLGA) nanoparticles that bind and internalize in HER2-overexpressing breast cancer cells, enabling potent anti-tumor activity. To overcome the problems associated with the short half-lives of this drug...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2009-06, Vol.374 (1), p.145-152
Main Authors: Gao, Jie, Zhong, Wei, He, Jinqiu, Li, Huimei, Zhang, He, Zhou, Guichen, Li, Bohua, Lu, Ying, Zou, Hao, Kou, Geng, Zhang, Dapeng, Wang, Hao, Guo, Yajun, Zhong, Yanqiang
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443
cites cdi_FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443
container_end_page 152
container_issue 1
container_start_page 145
container_title International journal of pharmaceutics
container_volume 374
creator Gao, Jie
Zhong, Wei
He, Jinqiu
Li, Huimei
Zhang, He
Zhou, Guichen
Li, Bohua
Lu, Ying
Zou, Hao
Kou, Geng
Zhang, Dapeng
Wang, Hao
Guo, Yajun
Zhong, Yanqiang
description We previously reported the development of PE38KDEL-loaded anti-HER2 poly(lactic-co-glycolic acid) (PLGA) nanoparticles that bind and internalize in HER2-overexpressing breast cancer cells, enabling potent anti-tumor activity. To overcome the problems associated with the short half-lives of this drug delivery system, we have constructed PE38KDEL-loaded anti-HER2 PEGylated liposomes (PE-HER-liposomes). PE-HER-liposomes were constructed with Fab′ of recombinant humanized anti-HER2 monoclonal antibody (anti-HER2 Fab′) covalently linked to PEGylated liposomes containing PE38KDEL (PE-liposomes). We attached anti-HER2 Fab′ to the terminus of PEG (polyethylene glycol) on PEGylated liposomes. Incorporation of pyridylthiopropionoylamino-PEG-distearoylphosphatidylethanolamine (PDP-PEG-DSPE) into PEGylated liposomes followed by mild thiolysis of the PDP groups resulted in the formation of reactive thiol groups at the periphery of the liposomes. Efficient attachment of maleimide-derivatized anti-HER2 Fab′ took place under mild conditions. The characterization of PE-HER-liposomes, such as particle size, was evaluated by dynamic light-scattering detector. The Micro BCA method was used to determine the encapsulation efficiency of PE38KDEL and the quantity of conjugated Fab′. Flow cytometry and confocal microscopy showed that PE-HER-liposomes possessed receptor-specific binding and internalization for HER2-overexpressing SK-BR3 cells. Remarkably, PE-HER-liposomes were more cytotoxic than non-targeted PE-liposomes in HER2-overexpressing breast cancer cells. In conclusion, PE-HER-liposomes could serve as a promising therapeutic candidate for the treatment of HER2-overexpressing breast cancers.
doi_str_mv 10.1016/j.ijpharm.2009.03.018
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20644085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517309001434</els_id><sourcerecordid>20644085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443</originalsourceid><addsrcrecordid>eNqFkE1P20AQhleoCFLgJ1DlUm42s9_2qaogJYhIIATn1WY9phv5I921I-Xfs1Gs9tjTSDPPzLx6CLmmkFOg6naT-832tw1tzgDKHHgOtDghM1ponnGh1RcyA66LTFLNz8nXGDcAoBjlZ-SclkIoremMLN_Gtg_ZYMMHDljNXxa8eLpfrOYVNn6HYT_feZu6D_vGHua2G3y2XLyyuW_bsesbv-1j32K8JKe1bSJeTfWCvP9avN0ts9Xzw-Pdz1XmBBNDSiZVCVyJQhaWr63Qdal5xVjlaAkgFZcKNEuA1KLmkmmEEtayLoW2KTW_IDfHu9vQ_xkxDqb10WHT2A77MRoGSggoZALlEXShjzFgbbbBtzbsDQVzUGg2ZlJoDgoNcJMUpr1v04Nx3WL1b2tyloDvE2Cjs00dbOd8_MsxKoVgJU_cjyOHScfOYzDReewcVj6gG0zV-_9E-QTmyI52</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20644085</pqid></control><display><type>article</type><title>Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes</title><source>Elsevier</source><creator>Gao, Jie ; Zhong, Wei ; He, Jinqiu ; Li, Huimei ; Zhang, He ; Zhou, Guichen ; Li, Bohua ; Lu, Ying ; Zou, Hao ; Kou, Geng ; Zhang, Dapeng ; Wang, Hao ; Guo, Yajun ; Zhong, Yanqiang</creator><creatorcontrib>Gao, Jie ; Zhong, Wei ; He, Jinqiu ; Li, Huimei ; Zhang, He ; Zhou, Guichen ; Li, Bohua ; Lu, Ying ; Zou, Hao ; Kou, Geng ; Zhang, Dapeng ; Wang, Hao ; Guo, Yajun ; Zhong, Yanqiang</creatorcontrib><description>We previously reported the development of PE38KDEL-loaded anti-HER2 poly(lactic-co-glycolic acid) (PLGA) nanoparticles that bind and internalize in HER2-overexpressing breast cancer cells, enabling potent anti-tumor activity. To overcome the problems associated with the short half-lives of this drug delivery system, we have constructed PE38KDEL-loaded anti-HER2 PEGylated liposomes (PE-HER-liposomes). PE-HER-liposomes were constructed with Fab′ of recombinant humanized anti-HER2 monoclonal antibody (anti-HER2 Fab′) covalently linked to PEGylated liposomes containing PE38KDEL (PE-liposomes). We attached anti-HER2 Fab′ to the terminus of PEG (polyethylene glycol) on PEGylated liposomes. Incorporation of pyridylthiopropionoylamino-PEG-distearoylphosphatidylethanolamine (PDP-PEG-DSPE) into PEGylated liposomes followed by mild thiolysis of the PDP groups resulted in the formation of reactive thiol groups at the periphery of the liposomes. Efficient attachment of maleimide-derivatized anti-HER2 Fab′ took place under mild conditions. The characterization of PE-HER-liposomes, such as particle size, was evaluated by dynamic light-scattering detector. The Micro BCA method was used to determine the encapsulation efficiency of PE38KDEL and the quantity of conjugated Fab′. Flow cytometry and confocal microscopy showed that PE-HER-liposomes possessed receptor-specific binding and internalization for HER2-overexpressing SK-BR3 cells. Remarkably, PE-HER-liposomes were more cytotoxic than non-targeted PE-liposomes in HER2-overexpressing breast cancer cells. In conclusion, PE-HER-liposomes could serve as a promising therapeutic candidate for the treatment of HER2-overexpressing breast cancers.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2009.03.018</identifier><identifier>PMID: 19446771</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>ADP Ribose Transferases - immunology ; ADP Ribose Transferases - pharmacokinetics ; ADP Ribose Transferases - pharmacology ; Bacterial Toxins - immunology ; Bacterial Toxins - pharmacokinetics ; Bacterial Toxins - pharmacology ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - immunology ; Cell Line, Tumor ; Cytotoxicity ; Drug Delivery Systems ; Exotoxins - immunology ; Exotoxins - pharmacokinetics ; Exotoxins - pharmacology ; Female ; Flow Cytometry ; General pharmacology ; Half-Life ; Humans ; Immunoglobulin Fab Fragments - immunology ; Liposomes ; Medical sciences ; Particle Size ; PE38KDEL ; PEGylated immunoliposomes ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Polyethylene Glycols - chemistry ; Pseudomonas aeruginosa Exotoxin A ; Receptor, ErbB-2 - immunology ; RhuMAbHER2 ; Sulfhydryl Compounds - chemistry ; Virulence Factors - immunology ; Virulence Factors - pharmacokinetics ; Virulence Factors - pharmacology</subject><ispartof>International journal of pharmaceutics, 2009-06, Vol.374 (1), p.145-152</ispartof><rights>2009 Elsevier B.V.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443</citedby><cites>FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21544293$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19446771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Jie</creatorcontrib><creatorcontrib>Zhong, Wei</creatorcontrib><creatorcontrib>He, Jinqiu</creatorcontrib><creatorcontrib>Li, Huimei</creatorcontrib><creatorcontrib>Zhang, He</creatorcontrib><creatorcontrib>Zhou, Guichen</creatorcontrib><creatorcontrib>Li, Bohua</creatorcontrib><creatorcontrib>Lu, Ying</creatorcontrib><creatorcontrib>Zou, Hao</creatorcontrib><creatorcontrib>Kou, Geng</creatorcontrib><creatorcontrib>Zhang, Dapeng</creatorcontrib><creatorcontrib>Wang, Hao</creatorcontrib><creatorcontrib>Guo, Yajun</creatorcontrib><creatorcontrib>Zhong, Yanqiang</creatorcontrib><title>Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>We previously reported the development of PE38KDEL-loaded anti-HER2 poly(lactic-co-glycolic acid) (PLGA) nanoparticles that bind and internalize in HER2-overexpressing breast cancer cells, enabling potent anti-tumor activity. To overcome the problems associated with the short half-lives of this drug delivery system, we have constructed PE38KDEL-loaded anti-HER2 PEGylated liposomes (PE-HER-liposomes). PE-HER-liposomes were constructed with Fab′ of recombinant humanized anti-HER2 monoclonal antibody (anti-HER2 Fab′) covalently linked to PEGylated liposomes containing PE38KDEL (PE-liposomes). We attached anti-HER2 Fab′ to the terminus of PEG (polyethylene glycol) on PEGylated liposomes. Incorporation of pyridylthiopropionoylamino-PEG-distearoylphosphatidylethanolamine (PDP-PEG-DSPE) into PEGylated liposomes followed by mild thiolysis of the PDP groups resulted in the formation of reactive thiol groups at the periphery of the liposomes. Efficient attachment of maleimide-derivatized anti-HER2 Fab′ took place under mild conditions. The characterization of PE-HER-liposomes, such as particle size, was evaluated by dynamic light-scattering detector. The Micro BCA method was used to determine the encapsulation efficiency of PE38KDEL and the quantity of conjugated Fab′. Flow cytometry and confocal microscopy showed that PE-HER-liposomes possessed receptor-specific binding and internalization for HER2-overexpressing SK-BR3 cells. Remarkably, PE-HER-liposomes were more cytotoxic than non-targeted PE-liposomes in HER2-overexpressing breast cancer cells. In conclusion, PE-HER-liposomes could serve as a promising therapeutic candidate for the treatment of HER2-overexpressing breast cancers.</description><subject>ADP Ribose Transferases - immunology</subject><subject>ADP Ribose Transferases - pharmacokinetics</subject><subject>ADP Ribose Transferases - pharmacology</subject><subject>Bacterial Toxins - immunology</subject><subject>Bacterial Toxins - pharmacokinetics</subject><subject>Bacterial Toxins - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - immunology</subject><subject>Cell Line, Tumor</subject><subject>Cytotoxicity</subject><subject>Drug Delivery Systems</subject><subject>Exotoxins - immunology</subject><subject>Exotoxins - pharmacokinetics</subject><subject>Exotoxins - pharmacology</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>General pharmacology</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - immunology</subject><subject>Liposomes</subject><subject>Medical sciences</subject><subject>Particle Size</subject><subject>PE38KDEL</subject><subject>PEGylated immunoliposomes</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Pseudomonas aeruginosa Exotoxin A</subject><subject>Receptor, ErbB-2 - immunology</subject><subject>RhuMAbHER2</subject><subject>Sulfhydryl Compounds - chemistry</subject><subject>Virulence Factors - immunology</subject><subject>Virulence Factors - pharmacokinetics</subject><subject>Virulence Factors - pharmacology</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkE1P20AQhleoCFLgJ1DlUm42s9_2qaogJYhIIATn1WY9phv5I921I-Xfs1Gs9tjTSDPPzLx6CLmmkFOg6naT-832tw1tzgDKHHgOtDghM1ponnGh1RcyA66LTFLNz8nXGDcAoBjlZ-SclkIoremMLN_Gtg_ZYMMHDljNXxa8eLpfrOYVNn6HYT_feZu6D_vGHua2G3y2XLyyuW_bsesbv-1j32K8JKe1bSJeTfWCvP9avN0ts9Xzw-Pdz1XmBBNDSiZVCVyJQhaWr63Qdal5xVjlaAkgFZcKNEuA1KLmkmmEEtayLoW2KTW_IDfHu9vQ_xkxDqb10WHT2A77MRoGSggoZALlEXShjzFgbbbBtzbsDQVzUGg2ZlJoDgoNcJMUpr1v04Nx3WL1b2tyloDvE2Cjs00dbOd8_MsxKoVgJU_cjyOHScfOYzDReewcVj6gG0zV-_9E-QTmyI52</recordid><startdate>20090605</startdate><enddate>20090605</enddate><creator>Gao, Jie</creator><creator>Zhong, Wei</creator><creator>He, Jinqiu</creator><creator>Li, Huimei</creator><creator>Zhang, He</creator><creator>Zhou, Guichen</creator><creator>Li, Bohua</creator><creator>Lu, Ying</creator><creator>Zou, Hao</creator><creator>Kou, Geng</creator><creator>Zhang, Dapeng</creator><creator>Wang, Hao</creator><creator>Guo, Yajun</creator><creator>Zhong, Yanqiang</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20090605</creationdate><title>Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes</title><author>Gao, Jie ; Zhong, Wei ; He, Jinqiu ; Li, Huimei ; Zhang, He ; Zhou, Guichen ; Li, Bohua ; Lu, Ying ; Zou, Hao ; Kou, Geng ; Zhang, Dapeng ; Wang, Hao ; Guo, Yajun ; Zhong, Yanqiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>ADP Ribose Transferases - immunology</topic><topic>ADP Ribose Transferases - pharmacokinetics</topic><topic>ADP Ribose Transferases - pharmacology</topic><topic>Bacterial Toxins - immunology</topic><topic>Bacterial Toxins - pharmacokinetics</topic><topic>Bacterial Toxins - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - immunology</topic><topic>Cell Line, Tumor</topic><topic>Cytotoxicity</topic><topic>Drug Delivery Systems</topic><topic>Exotoxins - immunology</topic><topic>Exotoxins - pharmacokinetics</topic><topic>Exotoxins - pharmacology</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>General pharmacology</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - immunology</topic><topic>Liposomes</topic><topic>Medical sciences</topic><topic>Particle Size</topic><topic>PE38KDEL</topic><topic>PEGylated immunoliposomes</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Pseudomonas aeruginosa Exotoxin A</topic><topic>Receptor, ErbB-2 - immunology</topic><topic>RhuMAbHER2</topic><topic>Sulfhydryl Compounds - chemistry</topic><topic>Virulence Factors - immunology</topic><topic>Virulence Factors - pharmacokinetics</topic><topic>Virulence Factors - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gao, Jie</creatorcontrib><creatorcontrib>Zhong, Wei</creatorcontrib><creatorcontrib>He, Jinqiu</creatorcontrib><creatorcontrib>Li, Huimei</creatorcontrib><creatorcontrib>Zhang, He</creatorcontrib><creatorcontrib>Zhou, Guichen</creatorcontrib><creatorcontrib>Li, Bohua</creatorcontrib><creatorcontrib>Lu, Ying</creatorcontrib><creatorcontrib>Zou, Hao</creatorcontrib><creatorcontrib>Kou, Geng</creatorcontrib><creatorcontrib>Zhang, Dapeng</creatorcontrib><creatorcontrib>Wang, Hao</creatorcontrib><creatorcontrib>Guo, Yajun</creatorcontrib><creatorcontrib>Zhong, Yanqiang</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Jie</au><au>Zhong, Wei</au><au>He, Jinqiu</au><au>Li, Huimei</au><au>Zhang, He</au><au>Zhou, Guichen</au><au>Li, Bohua</au><au>Lu, Ying</au><au>Zou, Hao</au><au>Kou, Geng</au><au>Zhang, Dapeng</au><au>Wang, Hao</au><au>Guo, Yajun</au><au>Zhong, Yanqiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2009-06-05</date><risdate>2009</risdate><volume>374</volume><issue>1</issue><spage>145</spage><epage>152</epage><pages>145-152</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>We previously reported the development of PE38KDEL-loaded anti-HER2 poly(lactic-co-glycolic acid) (PLGA) nanoparticles that bind and internalize in HER2-overexpressing breast cancer cells, enabling potent anti-tumor activity. To overcome the problems associated with the short half-lives of this drug delivery system, we have constructed PE38KDEL-loaded anti-HER2 PEGylated liposomes (PE-HER-liposomes). PE-HER-liposomes were constructed with Fab′ of recombinant humanized anti-HER2 monoclonal antibody (anti-HER2 Fab′) covalently linked to PEGylated liposomes containing PE38KDEL (PE-liposomes). We attached anti-HER2 Fab′ to the terminus of PEG (polyethylene glycol) on PEGylated liposomes. Incorporation of pyridylthiopropionoylamino-PEG-distearoylphosphatidylethanolamine (PDP-PEG-DSPE) into PEGylated liposomes followed by mild thiolysis of the PDP groups resulted in the formation of reactive thiol groups at the periphery of the liposomes. Efficient attachment of maleimide-derivatized anti-HER2 Fab′ took place under mild conditions. The characterization of PE-HER-liposomes, such as particle size, was evaluated by dynamic light-scattering detector. The Micro BCA method was used to determine the encapsulation efficiency of PE38KDEL and the quantity of conjugated Fab′. Flow cytometry and confocal microscopy showed that PE-HER-liposomes possessed receptor-specific binding and internalization for HER2-overexpressing SK-BR3 cells. Remarkably, PE-HER-liposomes were more cytotoxic than non-targeted PE-liposomes in HER2-overexpressing breast cancer cells. In conclusion, PE-HER-liposomes could serve as a promising therapeutic candidate for the treatment of HER2-overexpressing breast cancers.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>19446771</pmid><doi>10.1016/j.ijpharm.2009.03.018</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2009-06, Vol.374 (1), p.145-152
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_20644085
source Elsevier
subjects ADP Ribose Transferases - immunology
ADP Ribose Transferases - pharmacokinetics
ADP Ribose Transferases - pharmacology
Bacterial Toxins - immunology
Bacterial Toxins - pharmacokinetics
Bacterial Toxins - pharmacology
Biological and medical sciences
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - immunology
Cell Line, Tumor
Cytotoxicity
Drug Delivery Systems
Exotoxins - immunology
Exotoxins - pharmacokinetics
Exotoxins - pharmacology
Female
Flow Cytometry
General pharmacology
Half-Life
Humans
Immunoglobulin Fab Fragments - immunology
Liposomes
Medical sciences
Particle Size
PE38KDEL
PEGylated immunoliposomes
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Polyethylene Glycols - chemistry
Pseudomonas aeruginosa Exotoxin A
Receptor, ErbB-2 - immunology
RhuMAbHER2
Sulfhydryl Compounds - chemistry
Virulence Factors - immunology
Virulence Factors - pharmacokinetics
Virulence Factors - pharmacology
title Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T23%3A14%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor-targeted%20PE38KDEL%20delivery%20via%20PEGylated%20anti-HER2%20immunoliposomes&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Gao,%20Jie&rft.date=2009-06-05&rft.volume=374&rft.issue=1&rft.spage=145&rft.epage=152&rft.pages=145-152&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/j.ijpharm.2009.03.018&rft_dat=%3Cproquest_cross%3E20644085%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20644085&rft_id=info:pmid/19446771&rfr_iscdi=true